MODULATING EFFECT OF MITOMYCIN OR CISPLATIN ON LYMPHOKINE-ACTIVATED KILLER-CELL PROLIFERATION AND ANTITUMOR-ACTIVITY TO BLADDER-CANCER CELL-LINES IN-VITRO

ATM: To study the effect of mitomycin (Mit) or cisplatin ( Cis) on the proliferation of lymphokine-activated killer (LAK) cells in patients with transitional cell cancer of bladder and their cytolysis to bladde r tumor cells. METHODS: LAK cell proliferation was assayed in the pres ence of Mit or Cis by cell counting. Bladder cancer cell lines BIU-87 and EJ were cultured as target cells and cytotoxicity of LAK cells was determined by (4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom ide (MTT) assay. RESULTS: The proliferation of LAK cells induced by re combinant interleukin-2 (IL-2) was inhibited by Cis in a concentration -dependent manner and was decreased to 55.3 % at 100 mg.L-1 compared w ith control at 96 h. The enhanced growth of the LAK cells was observed with Mit 5 - 10 mg.L-1 from 48 to 96 h. Cis 10 mg.L-1 increased the c ytotoxicity against BIU-87 and EJ cells. CONCLUSION: Immunomodulatory effect of chemotherapeutic agents on LAK cell proliferation induced by IL-2 in patients with bladder cancer mainly depends on the drug itsel f.